This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease


Guo, Qihao, Zhou, Yan, Wang, Chao-Jih, Huang, Young-Ming, Lee, Yi-Ta, Su, Muh-Hwan, Lu, Jiahong


American Journal Of Alzheimer's Disease And Other Dementias, Volume: 28, No.: 4, Pages.: 363-370

Year of Publication



Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed Behavioral Scale, and Clinical Global Impression (CGI) scales.; Results: The MMSE score was 14.78 ± 2.51 at baseline and 14.06 ± 4.26 at study completion. While changes in ADAS-cog score before and after 48 weeks of treatment were statistically insignificant, the score improved, deteriorated, and remained unchanged in 10, 7, and 1 patients, respectively. The ADL and CGI scores showed no significant difference from baseline. All adverse reactions were mild.; Conclusion: After Memoregain(®) treatment, patients with AD showed no obvious aggravation of cognitive function, independent living ability, and overall conditions but were stable throughout the study. Comparison with other long-term medications with acetylcholinesterase inhibitors suggests that Memoregain(®) has a potential to be a possible treatment option for mild to moderate AD. Large trials with bigger population are required to confirm.;

Bibtex Citation

@article{Guo_2013, doi = {10.1177/1533317513488907}, url = {}, year = 2013, month = {may}, publisher = {{SAGE} Publications}, volume = {28}, number = {4}, pages = {363--370}, author = {Q. Guo and Y. Zhou and C.-J. Wang and Y.-M. Huang and Y.-T. Lee and M.-H. Su and J. Lu}, title = {An Open-Label, Nonplacebo-Controlled Study on Cistanche tubulosa Glycoside Capsules (Memoregain(R)) for Treating Moderate Alzheimer{textquotesingle}s Disease}, journal = {American Journal of Alzheimer{textquotesingle}s Disease and Other Dementias} }


activities of daily living, administration & dosage, adverse effects, aged, aged, 80 and over, alzheimer disease, alzheimer’s disease, apoptosis inhibition, capsule, capsules, chemistry, cistanche, cistanche tubulosa glycosides, clinical trial, cognition, ctg, drug effects, drug therapy, female, glycoside, glycosides, humans, male, methods, middle aged, nerve cells, phytotherapy, plant preparations, severity of illness index, therapeutic use, treatment outcome, tubulosa

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements